4//SEC Filing
White Mark K. 4
Accession 0001104659-24-077836
CIK 0001477845other
Filed
Jul 2, 8:00 PM ET
Accepted
Jul 3, 5:18 PM ET
Size
10.5 KB
Accession
0001104659-24-077836
Insider Transaction Report
Form 4
White Mark K.
Director
Transactions
- Award
Stock Option (right to buy)
2023-11-27+2,146→ 2,146 totalExercise: $7.39Exp: 2033-11-27→ Common Stock (2,146 underlying) - Award
Stock Option (right to buy)
2023-11-17+26,200→ 26,200 totalExercise: $6.07Exp: 2033-11-17→ Common Stock (26,200 underlying) - Award
Stock Option (right to buy)
2024-07-01+20,000→ 20,000 totalExercise: $5.27Exp: 2034-07-01→ Common Stock (20,000 underlying)
Footnotes (4)
- [F1]On June 12, 2024, stockholders of Annovis Bio, Inc. ("the Company") approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved.
- [F2]The stock option shall vest immediately upon grant date.
- [F3]The stock option was granted in consideration for consulting services that reporting person will perform for the Company.
- [F4]The stock option shall vest in quarterly increments, based upon the services performed by the reporting person under the related Consulting Agreement.
Documents
Issuer
Annovis Bio, Inc.
CIK 0001477845
Entity typeother
Related Parties
1- filerCIK 0001786183
Filing Metadata
- Form type
- 4
- Filed
- Jul 2, 8:00 PM ET
- Accepted
- Jul 3, 5:18 PM ET
- Size
- 10.5 KB